Jiahua C. Ji
Changchun, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
A syringeable immunotherapeutic hydrogel enhances T cell immunity via in-situ activation of STING pathway for advanced breast cancer postoperative therapy.
Journal: Frontiers in immunology
Published: November 06, 2024
CircDUSP16 mediates the effect of triple-negative breast cancer in pirarubicin via the miR-1224-3p/TFDP2 axis.
Journal: Biochemical pharmacology
Published: August 20, 2024
circSTIL mediates pirarubicin inhibiting the malignant phenotype of triple-negative breast cancer and acts as a biomarker in plasma exosomes.
Journal: Molecular immunology
Published: August 17, 2024
Erratum: CircZCCHC2 decreases pirarubicin sensitivity and promotes triple-negative breast cancer development via the miR-1200/TPR axis.
Journal: iScience
Published: May 06, 2024
Adenylate cyclase 1 knockdown attenuates pirarubicin-induced cardiotoxicity.
Journal: Clinical and experimental pharmacology & physiology
Published: April 29, 2024
LncRNA Miat knockdown enhances pirarubicin-mediated anticancer sensitivity in breast cancer cells.
Journal: Environmental toxicology
Published: July 05, 2023
CircEGFR reduces the sensitivity of pirarubicin and regulates the malignant progression of triple-negative breast cancer via the miR-1299/EGFR axis.
Journal: International journal of biological macromolecules
Published: April 27, 2023
LncRNA Miat knockdown protects against pirarubicin-induced cardiotoxicity by targeting miRNA-129-1-3p.
Journal: Environmental toxicology
Published: April 08, 2023
MiR-494-3p aggravates pirarubicin-induced cardiomyocyte injury by regulating MDM4/p53 signaling pathway.
Journal: Environmental toxicology
Published: March 07, 2023
Astaxanthin protects against pirarubicin-induced H9c2 cardiomyocytes by adjusting microRNA-494-3p-mediated MDM4/p53 signalling pathway.
Journal: The Journal of pharmacy and pharmacology
Published: January 10, 2023
Identification of prognostic genes signature and construction of ceRNA network in pirarubicin treatment of triple-negative breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: October 26, 2022
Last Updated: 09/26/2026